SCHEMBL5723080

SCHEMBL5723080

COc1ccc(C(C)=O)c2c1OC1(CCCC1)C2

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
KDM4E B2RXH2 2/20 0.50
ALDH1A1 P00352 1/20 0.50
HSD17B10 Q99714 1/20 0.50
PDE4A P27815 10/20 0.47
PDE4B Q07343 9/20 0.47
PDE4C Q08493 9/20 0.47
PDE4D Q08499 9/20 0.47
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
CA9 Q16790 2/20 0.35
MRGPRX2 Q96LB1 1/20 0.35
KMT2A Q03164 1/20 0.35
TSHR P16473 1/20 0.34
CASP1 P29466 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5722999 0.88 PDE4A (0.47) LMNAKDM4EALDH1A1HSD17B10PDE4A
SCHEMBL5723198 0.87 PDE4A (0.46) LMNAKDM4EALDH1A1HSD17B10PDE4A
SCHEMBL5722811 0.82 KDM4E (0.54) LMNAKDM4EALDH1A1HSD17B10PDE4A
SCHEMBL5722892 0.81 PDE4A (0.43) LMNAKDM4EALDH1A1HSD17B10PDE4A
SCHEMBL5723031 0.80 PDE4A (0.42) LMNAKDM4EALDH1A1HSD17B10PDE4A
SCHEMBL5722734 0.80 PDE4A (0.43) LMNAPDE4APDE4BPDE4CPDE4D
Hydrochloric Acid SCHEMBL5723210 0.79 PDE4A (0.43) LMNAPDE4APDE4BPDE4CPDE4D
SCHEMBL5722977 0.79 CYP19A1 (0.43) LMNAPDE4APDE4BPDE4CPDE4D
SCHEMBL129925 0.79 PDE4D (0.49) LMNAKDM4EPDE4APDE4BPDE4C
SCHEMBL5723109 0.78 ALDH1A1 (0.40) LMNAKDM4EALDH1A1HSD17B10PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0771794-B1 OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO KK (JP) 2006-05-03 EP disclosed
US-6716987-B1 PHOSPHODIESTERASE IV INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-04-06 US disclosed
US-6514996-B2 Derivatives of benzofuran or benzodioxole KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-02-04 US disclosed
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-09-12 US disclosed
EP-0771794-A1 OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO CO., LTD. (JP) 1997-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE CBR1, CBR3, CYC1 LMNA 1848/4885KDM4E 3975/4885ALDH1A1 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.